Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
We’re attending the @sitcancer Meeting!
Join us as we discuss the activity of CAN-3110 in a model of #melanoma. CAN-3110 is a selectively replicating oncolytic herpes simplex virus designed to target & kill cancer cells expressing Nestin.
https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-preclinical-data-therapeutic
$CADL #SITC24
Thank you, @LongwoodLeaders, for organizing an amazing meeting and thanks to my colleagues on the panel for an outstanding discussion of ‘Identifying next generation therapeutics’
Over 1.3 million Americans are living with a #braintumor.
Brain Tumor Awareness Week is dedicated to raising #awareness about the challenges faced by those diagnosed, highlighting the need for specialized responses and for increased research efforts.
https://theibta.org/awareness-raising/ibtaw-toolkit/
